18:52 , Feb 7, 2019 |  BC Week In Review  |  Clinical News

Aminex shows MYCN is a regulator of the polyamine pathway

Researchers from Aminex Therapeutics Inc. (Seattle, Wash.) and University of New South Wales showed that the MYCN oncogene is a direct regulator of the polyamine pathway, suggesting a new approach to hitting the otherwise undrugggable...
20:31 , Feb 1, 2019 |  BC Extra  |  Preclinical News

Aminex shows MYCN is a regulator of the polyamine pathway

Researchers from Aminex Therapeutics Inc. (Seattle, Wash.) and University of New South Wales showed that the MYCN oncogene is a direct regulator of the polyamine pathway, suggesting a new approach to hitting the otherwise undrugggable...
19:02 , Jun 22, 2018 |  BC Week In Review  |  Financial News

Aminex raises $10M, starts Phase I cancer trial

Aminex Therapeutics Inc. (Seattle, Wash.) raised $10 million on June 20 in an untranched series B round. The company declined to name its investors. The company also said it dosed the first patient in a...
14:24 , Jun 20, 2018 |  BC Extra  |  Financial News

Aminex raises $10M, starts Phase I cancer trial

Aminex Therapeutics Inc. (Seattle, Wash.) raised $10 million in an untranched series B round. The company declined to name its investors. The company said Wednesday that it dosed the first patient in a Phase I...